Remarkably, IL-17A expression by tumor cells markedly potentiates the treatment efficacy of anti-Gr1-mediated and anti-G-CSF-mediated MDSC depletion therapies that are otherwise not effective in preventing lung metastasis in 4T1 tumor-bearing mice. This evidence concerns the gene CSF3 and neoplasm.